Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia - PubMed (original) (raw)
. 1998 Apr;101(4 Pt 1):583-90.
doi: 10.1542/peds.101.4.583.
Affiliations
- PMID: 9521938
- DOI: 10.1542/peds.101.4.583
Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia
B L Therrell Jr et al. Pediatrics. 1998 Apr.
Abstract
Objective: To assess results of newborn screening for 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH) in Texas over 6 years of screening 1.9 million infants.
Methods: In 1989, CAH was incorporated into the ongoing Texas Newborn Screening Program, which requires two screens on each newborn. 17-Hydroxyprogesterone was assayed, without extraction, by radioimmunoassay of blood collected from heel sticks onto filter paper collection cards. Infants with elevated levels of 17-hydroxyprogesterone were referred for evaluation, and those considered to have CAH were studied with respect to disease characteristics. Data were collected by pediatric endocrinologists using standardized forms that included type of CAH, results of laboratory tests, treatment regimen, disease symptoms and signs, and, for girls, degree of genital virilization.
Results: The incidence of classic CAH in Texas is 1:16 008, with a ratio of salt-wasting to simple-virilizing of 2.7:1. A majority of infants detected were undiagnosed until screened, despite signs of salt-wasting or ambiguous genitalia. It was difficult to differentiate salt-wasting from simple-virilizing CAH in infants who were identified before the onset of adrenal insufficiency or electrolyte abnormalities. A substantial number of infants with nonclassic (NC) CAH also were detected. Not all infants were detected on the initial screen; 14% of infants with classic CAH and 87% with NC CAH were detected on the second routine screening test.
Conclusions: Our findings confirm the benefits of newborn screening for CAH and the importance of a second screening test, and suggest that programs for newborn CAH screening must consider complex issues in diagnosis and treatment. These results also confirm that CAH is a continuum of disorders, rather than a disorder with discrete subtypes. In addition, the difficulties in differentiating CAH subtypes in newborns, and thus deciding appropriate treatment, and the high incidence of NC CAH suggest that standard diagnostic criteria and treatment regimens for CAH may need modification. Where screening exists, physicians will encounter more cases of CAH than in the past.
Similar articles
- Effect of newborn screening for congenital adrenal hyperplasia.
Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, Riley WJ. Brosnan PG, et al. Arch Pediatr Adolesc Med. 1999 Dec;153(12):1272-8. doi: 10.1001/archpedi.153.12.1272. Arch Pediatr Adolesc Med. 1999. PMID: 10591305 - Newborn screening for congenital adrenal hyperplasia.
Therrell BL. Therrell BL. Endocrinol Metab Clin North Am. 2001 Mar;30(1):15-30. doi: 10.1016/s0889-8529(08)70017-3. Endocrinol Metab Clin North Am. 2001. PMID: 11344933 Review. - Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
Kopacek C, de Castro SM, Prado MJ, da Silva CM, Beltrão LA, Spritzer PM. Kopacek C, et al. BMC Pediatr. 2017 Jan 17;17(1):22. doi: 10.1186/s12887-016-0772-x. BMC Pediatr. 2017. PMID: 28095810 Free PMC article. - Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states.
Held PK, Shapira SK, Hinton CF, Jones E, Hannon WH, Ojodu J. Held PK, et al. Mol Genet Metab. 2015 Nov;116(3):133-8. doi: 10.1016/j.ymgme.2015.08.004. Epub 2015 Aug 12. Mol Genet Metab. 2015. PMID: 26296712 Free PMC article. - [Congenital adrenal hyperplasia].
Stanić M, Nesović M. Stanić M, et al. Med Pregl. 1999 Nov-Dec;52(11-12):447-54. Med Pregl. 1999. PMID: 10748766 Review. Croatian.
Cited by
- In-depth exploration of differences of sex development: 5-year experience in a tertiary center.
Hssaini M, Abourazzak S, El Otmani I, Ahakoud M, Ameli A, Bouguenouch L, Bekkari H. Hssaini M, et al. Endocr Connect. 2024 Sep 13;13(10):e240236. doi: 10.1530/EC-24-0236. Print 2024 Oct 1. Endocr Connect. 2024. PMID: 39150057 Free PMC article. - Characteristics of Patients with Classic Congenital Adrenal Hyperplasia Missed on the Newborn Screen.
Saroufim R, Nebesio TD, Eugster EA. Saroufim R, et al. Horm Res Paediatr. 2024;97(5):470-476. doi: 10.1159/000535405. Epub 2023 Nov 22. Horm Res Paediatr. 2024. PMID: 37992692 Free PMC article. - Differences in Hyperandrogenism Related to Early Detection of Non-Classical Congenital Adrenal Hyperplasia on Second Newborn Screen.
McCann-Crosby B, Liang MC, Geffner ME, Koppin CM, Fraga NR, Sutton VR, Karaviti LP, Bhullar G, Kim MS. McCann-Crosby B, et al. Int J Neonatal Screen. 2023 Sep 1;9(3):50. doi: 10.3390/ijns9030050. Int J Neonatal Screen. 2023. PMID: 37754776 Free PMC article. - Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States.
Harasymiw LA, Grosse SD, Cullen KR, Bitsko RH, Perou R, Sarafoglou K. Harasymiw LA, et al. Front Endocrinol (Lausanne). 2023 Aug 17;14:1129584. doi: 10.3389/fendo.2023.1129584. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37664854 Free PMC article. - Epidemiology and Causes of Primary Adrenal Insufficiency in Children: A Population-Based Study.
Borchers J, Pukkala E, Mäkitie O, Laakso S. Borchers J, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2879-2885. doi: 10.1210/clinem/dgad283. J Clin Endocrinol Metab. 2023. PMID: 37216903 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous